KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Share-based Compensation (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Share-based Compensation data on record, last reported at $45.7 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 8.05% year-over-year to $45.7 million; the TTM value through Dec 2025 reached $139.1 million, down 30.31%, while the annual FY2025 figure was $139.1 million, 24.54% down from the prior year.
  • Share-based Compensation reached $45.7 million in Q4 2025 per SRPT's latest filing, up from $14.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $102.9 million in Q2 2022 and bottomed at $14.9 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $43.4 million, with a median of $45.8 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 254.8% in 2022, then crashed 69.63% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $29.7 million in 2021, then soared by 69.82% to $50.5 million in 2022, then dropped by 9.27% to $45.8 million in 2023, then rose by 8.45% to $49.7 million in 2024, then dropped by 8.05% to $45.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $45.7 million in Q4 2025, $14.9 million in Q3 2025, and $31.9 million in Q2 2025.